Aptus Pharma IPO Allotment Status; Steps to verify status.
The public subscription window for Aptus Pharma SME IPO was open from September 23, 2025, to September 25, 2025. The basis of allotment will be finalised today, September 26, 2025. Here’s how you can check the IPO allotment status on BSE and registrar’s website.
Procedure to Check Aptus Pharma IPO Allotment Status Online On BSE
- Click here to visit the application status page.
- In Issue Type, “Equity”.
- In Issue Name, select “Aptus Pharma Limited”.
- Enter your “Application No.” or “PAN No.”
- Click on “I am not a robot”.
- Click “Submit”.
Procedure to Check Aptus Pharma IPO Allotment Status on Bigshare Services Pvt Ltd (Registrar to the issue)
- Visit the Bigshare Services IPO allotment status page here.
- Click any of the server links.
- In Company Selection, select “Aptus Pharma”.
- Enter either your application number, beneficiary ID or PAN.
- Enter the captcha and click “Search”.
IPO Details
Aptus Pharma IPO is a book-building issue of ₹13.02 crores, consisting entirely of a fresh issue of 0.19 crore shares. The price band is set at ₹65 to ₹70 per share. The tentative listing on BSE SME is September 30, 2025.
Interactive Financial Services Ltd is the book-running lead manager, and Bigshare Services Pvt Ltd is the registrar for the issue.
Use of Proceeds
The net proceeds from the fresh issue will be used to
- Fund working capital requirements
- Fund capital expenditure for office premises with furniture and industrial racks.
- General corporate purposes
Aptus Pharma IPO – Overall Subscription Status
(September 25, 2025, end of the day)
|
Category |
Subscription (times) |
|
Qualified Institutional Buyers (QIBs) |
1.24 |
|
Non-Institutional Investors |
28.75 |
|
Individual Investors (IND category bidding for 2 Lots) |
31.43 |
|
Total |
22.27 |
Aptus Pharma Business Overview
Aptus Pharma is engaged in the marketing and distribution of finished pharmaceutical formulations through a contract manufacturing model. The company itself doesn’t own any manufacturing plants but has partnered with seven manufacturing units.
Aptus' product portfolio comprises Aptus Pharma (Pioneer Division), Aptus CD Care (Cardiac Diabetic Division), Aptus Wellcare (Wellcare Division), and Aptus Global (Export Division).
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.